Doc code: IDS
`
`PTOISBI'DBa (03-15)
`Approved for use through 071312016. OMB 0651-0031
`Doc description: Information Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`IN FORMATION DISCLOSU RE
`
`
`Application Number
`Filing Date
`
`First Named Inventor
`
`
`
`
`| 5121623
`
`
`
`I016—08—25
`ecilia Anna Wilhelmina GEUIJ EN
`
`
`
`
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`
`1 642
`
`
`Examiner Name
`Not Yet Assigned
`I MRX5—01TUS
`
`Attorney Docket Number
`
`-—
`
`
`——+————— :rm5m3 9.. E
`
`
`
`U.S.PATENTS
`
`Examiner C'te
`
`Patent Number
`
`Kind
`Code1
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`
`989-01 -31
`
`989—03—28
`
`abilly et al.
`
`992-09-29
`
`998-03-24
`
`arter et al.
`
`O A ‘F’O A -05
`
`arter et al.
`
`o A ‘F’:24|}.M«i
`
`O A ‘1”O A -08
`
`= ates et al.
`
`O A ‘1” A A -26
`
`annan et al.
`
`‘
`
`‘
`
`‘
`
`‘
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`--
`
`642228
`
`705103
`
`EFS Web 2.1.17
`
`
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
` Application Number
`
`Add
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`Publication
`Number
`
`Publication
`Date
`
`of cited Document
`
`'0030078385
`
`' 003-04-24
`
`‘ rathoon et al.
`
`'0040071696
`
`004—04—15
`
`‘ dams et al.
`
`'0060212956
`
`' 006-09-21
`
`rocker et al.
`
`'0090191559
`
`uang et al.
`
`EFS Web 2.1.17
`
`
`
`I MRX5-01TUS If you wish to add additional US. Patent citation information please click the Add button.
`
`o A 'I"o A L 4:.
`
`umey et al.
`
`o A 9"o'.‘JoM
`
`Ie Kruif et al.
`
`o A 9"o'.‘JoM
`
`Ie Kruif et al.
`
`o A g:og:o-l
`
`Ie Kruif et al.
`
`‘
`
`‘
`
`‘
`
`‘
`
`‘
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`D _\ '7“D _\ —24
`' 009-07-30 Name of Patentee or Applicant
`
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
` Application Number
`
`"slU1
`
`A N
`
`A (A)
`
`A
`
`A
`
`U14k
`
`EFS Web 2.1.17
`
`AA
`
`AA
`
`A1
`
`A1
`
`A1
`
`A1
`
`AA
`
`AA
`
`AA
`
`_\_\
`
`A
`
`I MRX5-01TUS
`
`
`
`
`
`
`
`‘‘‘‘‘‘‘‘‘‘‘OOOOOOOOOOOAAAAAAAAAAC)(A)(A)(A)(A)NddOOO(DOOOOOOOOOOONdO00ddONOHdU1—|‘Nl00CCD‘NlCD—|CDCDCDU1—‘O5'4U1'40')U100NCDNCDCD(A)h—|(A)—|O)—|0')0U10!0U10')“'5'(A)dN"Nlon(Dd0')4:-w4:-wU1"Nl
`
`'009-07-16
`0'10-07-22
`'010-01-21
`'010-11-11
`'011-03-31
`'011-08-11
`'012-05-03
`'013-12-19
`'013-03-21
`'013-05-09
`'013-10-03
`
`CWHIRTER et al
`
`jaergaard et al.
`|
`| uferetal.
`|gawaetal.
`| annanetal.
`|Ioranz
`|
`| LISetal.
`|
`|.atesetal.
`| 0etal.
`|‘mleretal.
`
`. (D 7i-1E._... (Dp. E
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
` Application Number
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`
`Attorney Docket Number I MRX5-01TUS
`
`.I|
`II|
`.I|
`.I|
`II|
`
`
`
`'014-03-13
`'014-05-01
`0'14-05-22
`'015-05-21
`'015-07-16
`
`|eKruifetal.
`|.AKKERetal.
`|IEKRUIFetal
`|IeKruifetal.
`|eKruifetal.
`
`'015-01-15
`
`Iavies et al.
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.-
`FOREIGN PATENT DOCUMENTS
`
`
`
`Country
`OoD.(DN
`
`
`
`' 014/165855
`
`I4l009618
`
`' 008/027236
`
`Publication
`Code4 Date
`
` Kind
`
`A1
`
`A2
`
`A2
`
`2014—10—09
`
`2004—01—29
`
`2008—03—06
`
`
`
`
`
`
`
`
`Name of Patentee or
`
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`
`Passages or Relevant
`Figures Appear
`
`enentech, Inc
`
`
`
`
`
`
`Examiner Cite
`Foreign Document
`Number3
`'
`'
`
`
`
`
`
`
`
`
`
`
`EFS Web 2.1.17
`
`

`

`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
` Application Number
`
`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
`I MRX5-01TUS
`
`
`
`3-fl--fl-flfl 2013—10—24
`
`
`
`vvvvvvvvvvvDOCCDOOOOOOO_|_|C)C)_|_|_|_|_|C)C)J:-wonJ:-45(A)(A)NO(Dco-.-.-.m-.-.-.-.-.-.-.dddNC)dddddd(It(IIbLn0')(It00NQLn0CD‘NI0O‘NlIR(.31CD‘NI0L71(.0h(.0CDCDon-‘'HI0"0::U1CD0')U10::0')N‘slNO(A)(A)U14:0')J:-~I—lJ:
`
`2008—08—21
`
`
`
`'harmaceuticals, Inc
`
`2009—12—30
`
`erus B V
`
`A1
`
`2010—09—23
`
`enentech, Inc
`
`2012—09—20
`
`
`
`'harmaceuticals, Inc
`
`2013—09—12
`
`A1
`
`A1
`
`2013—10—24
`
`3
`
`20 1 4—04—24
`
`niversité‘lt Zfioench
`' rorektorat an
`
`
`
`3
`
`2013—06—19
`
`—l N
`
`2008—1 1—20
`
`niv Californina
`
`
`
`—l (A)
`
`4:.
`
`>
`
`2014—10—02
`
`
`
`'harmaceuticals, Inc
`
`EFS Web 2.1.1?
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
` Application Number
`
`I MRX5-01TUS
`
`
`
`3fl-flfl-fl-fl- 1996—09—06
`
`|\J|\J|\J—-No
`------‘‘co0U1.1;co_.oo'5aMm_|M_|_|onou‘4"oEEAAasrsam--'-Jotoo_\58wwoo:ooJ;_|_|
`
`Ui
`
`A_\
`
`2015—09—03
`
`erus B V
`
`-l-lwM
`
`A_\
`
`2015—09—03
`
`erus B V
`
`—l ‘4
`
`1984—10—03
`
`ELLTECH LTD
`
`A1
`
`1989—05—03
`
`: RISTOL MYERS CO
`
`1 992—04—22
`
`ELLCOME FOUND
`
`A1
`
`1993—01—20
`
`ELLCOME FOUND
`
`—|
`
`870459
`
`3
`
`2007—12—26
`
`' HARMACEUTICAL
`
`
`
`2000—10—26
`
`ntrogene Bv
`
`|\J00
`
`2003—01—16
`
`hromagenics Bv
`
`|\J4:.
`
`99602701 1
`
`enentech, Inc
`
`|\JUi
`
`998050431
`
`1998—11—12
`
`enentech, Inc
`
`EFS Web 2.1.1?
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
` Application Number
`
`I MRX5-01TUS
`
`
`
`
`3---fl-flflfl 2009—07—02
`
`
`vvvvvvvvvvvDOOOOOOOOOOOOOOOOOOOOO(D(D(DCDCD"-sl"-40')0')U1U1x.x.x.x.x._‘_‘_‘x.x.x.OOOCd4:.aOCdCCDCDCDCDd.4DU)NdO(DOOOCDtoMCDCDCD0ONNN(.0DDDCDCD(:3OU1U1U1U1_‘U1U1(A)(A)(Db(A)N—|(A)0')U1b
`
`|\J|\J"-40')
`
`|\JCO
`
`00000000|\J00N—‘O(.0
`
`2005—01—06
`
`2005—12—1 5
`
`2006—03—1 6
`
`A1
`
`2006—10—12
`
`2007—10—04
`
`A1
`
`2007—12—27
`
`3
`
`2008—10—09
`
`3
`
`2009—07—02
`
`004:.
`
`3
`
`2009—07—02
`
`00U1
`
`000')
`
`>
`
`2009—07—1 6
`
`EFS Web 2.1.1?
`
`enentech, Inc
`
`hugai Pharmaceutical
`
`
`
`ovo Nordisk As
`
`
`
`[
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`
`15121623
`
`
`Filing Date
`2016-08-25
`
` Application Number
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
`2009—08—1 3
`
`' ymeworks Inc
`
`A_\
`
`2009—04—23
`
`uvelo, Inc
`
`A1
`
`2010—07—29
`
`enmab As
`
`I MRX5-01TUS
`
`
`
`3Infl--fl-fl 2012—05—1 0
`
`
`vvvvvvvvvvvDOOOOOOOOOO_|_|_|_|_|_|_|_|_|C)C)J:-MMMdddC)C)(D(D-.D-.-.-.-.-.-.-.D-.OMdCdOCd0U10U1w00U1bNNNCD_\(D—lD—|CD00CDCD(.0-RCOCDhU1U1'HIU1(.0CD(.0-‘.4U1(A)9,U10')hU1U1O(D.h(DU3U10!U1(A)Nb"sl0')
`
`2010—11—11
`
`'harmaceuticals, Inc.
`
`A1
`
`2011—03—10
`
`I encor, Inc
`
`A1
`
`2011—03—10
`
`- mfit, Inc
`
`3
`
`2011—11—17
`
`
`
`' ymeworks Inc
`
`2012—10—04
`
`' harmaceuticals Sa
`
`
`
`20 1 2—02—23
`
`ovimmune Sa
`
`>
`
`20 1 4—04—03
`
`erus B V
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`—|
`
`4:-000000(.0CO"-I
`4:-4:-4:-00NC
`4:-4:-4:-O')U14:
`
`4:.N
`
`EFS Web 2.1.17
`
`

`

`
`
`
`
`Application Number 15121623
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`|1542
`
`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`
`
`MGENINC -
`
`ENENTECHINC -
`
`nstilestar Lexico—sciences,
`
` Attorney Docket Number
`
`.
` WER, MS, et al., "Cardiotoxicity of anticancer treatments: what the cardiologist needs to know," Nat Rev Cardiol, vol.
`’ (10):564—575 (2010)
`
`Examiner Name
`Not Yet Assigned
`I MRX5-01TUS
`
`' 01 1508604
`
`
`2011—03—17
`|.
`11600915 |. 1999—01—26
`
`'003/107218
`
`2003_12_24
`
`
`
`
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Examiner Cite
`|nitials*
`No
`
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`T5
`
`‘ LMAGRO, JC et al., "Humanization of antibodies," Front Biosci., vol. 13:1619—1633 (2008)
`
`‘ RTEAGA, CL et al., "Treatment of HERZ—positive breast cancer: current status and future perspectives," Nat Rev Clin
`oncol., vol.9(1):16—32 (2011)
`
`.ALKO, JM et al., "The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast
`-pithelium," Proc Natl Acad Sci U S A., vol.109(1):221—226 (2012)
`
`.ASELGA, J. et al., "Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer," N Engl J Med. vol.
`366(21):2018—2026 (2012)
`
`I EVASH, Y. et al, "Vertical transmission of human immunodeficiency virus is correlated with the absence of high—
`-ffinitylavidity maternal antibodies to the gp120 principal neutralizing domain," Proc Natl Acad Sci USA, vol. 87, pp.
`5445-3449 (1990)
`
`
`
`
`
`
`
`
`
`
`
`EFS Web 2.1.17
`
`

`

` Attorney Docket Number
`
`
`
`Examiner Name
`
`Not Yet Assigned
`
`
`
`—l—l54(A)N
`
`I MRX5-01TUS
`
`
`
`
`
`Application Number 15121623
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`|1542
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`RECO, WR et al., "The search for synergy: a critical review from a response surface perspective," Pharmacol Rev.,
`ol. 47(2):331-385 (1995)
`
`AIN, KK. et al,"A Prospective Randomized Comparison of Epirubicin and Doxorubicin in Patients With Advanced
`.reast Cancer," J Clin Oncol., vol. 3(6):818-820 (1985)
`
`UN'I'I'ILA, TT., et al, "Ligand-Independent HER2/HER3IPI3K Complex ls Disrupted by Trastuzumab and Is Effectively
`nhibited by the PI3K Inhibitor CDC-0941," Cancer Cell, vol.15, 429—440 (2009)
`
`UN'I'I'ILA, TT., et al,., "Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2—Amplified
`:reast Cancer," Cancer Res; 70(11):4481—4489 (2010)
`
`A NG, JC. et al., "Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer
`-IIs," MAbs, vol. 6(2):340—353 (2014)
`
`ANDGRAF, R., "HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks,"
`.reast Cancer Res. , vol. 9(1):202 (2007)
`
`IU, C. et al., "ADCC Enhancement Technologies for Next Generation TherapeuticAntibody," Trends in Biol
`'harmaceutcial Industry, 9 pages (2009)
`
`oCANA, A. et aI., "HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis," J Natl Cancer Inst., vo|.105
`4):266-2T3 (2013)
`
`—l—l—lLn4;
`
`'OBINSON, MK. et al, "Targeting ErbBZ and Erb33 with a bispecific single-chain Fv enhances targeting selectivity
`: nd induces a therapeutic effect in vitro," Br J Cancer, vol. 99(9):1415—1425 (2008)
`
`.CHOEBERL, B. et al, "An Erb33 antibody, MM-121, is active in cancers with ligand dependent activation," Cancer
`es., 70(6): 2485—2494 (2010)
`
`‘4
`
`.. ERGINA, NV. et al, "Escape from HER—family tyrosine kinase inhibitor therapy by the kinase—inactive HER3," Nature,
`ol. 445(7126):437—441(2007)
`
`EFS Web 2.1.17
`
`

`

`
`
`
`
`Application Number 15121623
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`|1542
`
` Attorney Docket Number
`
`
`
`Examiner Name
`
`Not Yet Assigned
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`
`
`I MRX5-01TUS
`
`HAMES, DS. et al., "High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable
`. iomarker in Patients with Squamous Cell Carcinomas of the Head and Neck," PLoS One, vol. 8(2): e56765, 10 pages
`2013)
`
`AN NER, M. et al., "Characterization of a novel cell line established from a patient with Herceptin—resistant breast
`ncer," Mol Cancer Ther., vol. 3(12): 1585—1592 (2004)
`
`|\JO
`
`HERY, JC. et al., "Resistance to human epidermal growth factor receptor type 2-targeted therapies," European
`ournal of Cancer, vol. 50: 892— 901(2014)
`
`—|
`
`ADHWA, D. et al., "Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: .
`etrospective study," Breast Cancer Res Treat, vol. 117: 357-364 (2009)
`
`EHRMAN TS. et al., "A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating
`rbBZ interactions," Proc Natl Acad Sci USA, vol. 103(50): 19063—19068 (2006)
`
`EIDLE, UH. et al., "The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer," Cancer
`enomics & Proteomics, vol. 10: 1-18 (2013)
`
`ILSON TR. et al., "Widespread potential for growth-factor—driven resistance to anticancer kinase inhibitors," Nature,
`ol. 487(7408): 505—509 (2012)
`
`ARDEN, Y. et al., "The ERBB network: at last, cancer therapy meets systems biology," Nat Rev Cancer, vol. 12:
`53—563 (2012)
`
`ONESAKA, K. et al,., "Activation of ERBBZ signaling causes resistance to the EGFR directed therapeutic antibody
`-tuximab," Sci Transl Med, vol. 3(99): 19 pages (2011)
`
`' HANG, H. et al., "ErbB receptors: from oncogenes to targeted cancer therapies," J. Clin. Invest. 117:2051—2058
`
`: UDAY, L. et al., "Epidermal Growth Factor Regulates the Exchange Rate of Guanine Nucleotides on p21ras in
`ibroblasts," Molecular and Cellular Biology, vol. 13(3):1903—1910 (1993)
`
`|\J|\J|\J|\J|\J
`
`|\J|\J"-l0')
`
`|\JCO
`
`EFS Web 2.1.17
`
`

`

`
`
`
`15121623
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`|1542
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
`OCHRAN, JR. et al., “Domain—level antibody epitope mapping through yeast surface display of epidermal growth
`actor receptor fragments," J Immunol Methods, vol. 287(1-2): 147-158 (2004)
`
`IE HAARD, HJ. et al., "A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation
`: nd Kinetic Analysis of High Affinity Antibodies‘," The Journal of Biological Chemistry, vol. 274(26): 18218-18230
`1999)
`
`ERGUSON, KM, "A structure-based view of Epidermal Growth Factor Receptor regulation," Annu Rev Biophys, vol.
`57: 353-373 (2008)
`
`ALE, NW. et al., "Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras," Nature, vol.
`563(6424):88—92 (1993)
`
`ARRETT, TP. et al., "Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to
`ransforming growth factor alpha," Cell, vol. 110 (6): 763-773 (2002)
`
`IARD, DJ. et al, "In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid
`umors," J Natl Cancer Inst., vol. 51, 1417-1423 (1973)
`
`ULLI, LF. et al, "Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine
`inase activity,"Cell Growth Differ, vol. 7(2):173—178 (1996)
`
`ORISSEN, RN. et al., "Epidermal growth factor receptor: mechanisms of activation and signalling," Exp Cell Res. vol.
`'84(1):31—53 (2003)
`
`
`
`
`I MRX5-01TUS
`
`00|\JO(D
`
`00 _.
`
`0000000000
`
`000003"-l
`
`00(D
`
`EFS Web 2.1.17
`
`UBOTA, T. et al, "Engineered therapeutic antibodies with improved effector functions," Cancer Sci., vol. 100:
`566-1572 (2009)
`
`EDCN, N. et al, "Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal
`-ntibodies nimotuzumab and cetuximab using different experimental animal models," Placenta, vol. 32: 531—534 (2011
`
`ICHTENBERGER, BM. et al., "Epidermal EGFR controls cutaneous host defense and prevents inflammation," Sci
`ransl Med, vol. 5 (199): 14 pages (2013)
`
`

`

`
`
`
`15121623
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`|1542
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
`ARKS, JD. et al., "By—passing Immunization Human Antibodies from V—gene Libraries Displayed on Phage," J Mol
`iol., vol. 222 :581-597 (1991)
`
`4:.
`
`4:-4:-4:-N—‘O
`4:-4:-4:---.|o)(It4:00
`4:-4:-4:-(D03
`
`
`
`
`I MRX5-01TUS
`
`ERLINO, GT. et al, "Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431
`uman Carcinoma Cells," Science, vol. 224(4647): 417-419 (1984)
`
`EULEMANS, EV. et al., "Selection of phage—displayed antibodies specific for a cytoskeletal antigen by competitive
`lution with a monoclonal antibody," J Mol Biol., vol. 244(4):353-360 (1994)
`
`oGlSO, H. et al., "Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular
`I omains," Cell, vol. 110: 775-787 (2002)
`
`o LAYIOYE, MA et al., "The ErbB signaling network: receptor heterodimerization in development and cancer," EMBO
`., vol. 19(13):3159—3167 (2000)
`
`'ASTORE, S. et al., "ERK1I2 Regulates Epidermal Chemokine Expression and Skin Inflammation," J. Immunol., vol.
`74:5047—5056 (2005)
`
`'ATEL, DK., "Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal
`. ncer," Pharmacotherapy, vol. 28(11 Pt 2):31 841 S (2008)
`
`'RIGENT, S et al., "Identification of c—erbB—3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF
`eceptorlc—erbB-3 chimera," EMBO J., vol.13(12):2831—2841(1994)
`
`'OBERTSON, SC. et al., "RTK mutations and human syndromes when good receptors turn bad," Trends Genet, vol.
`6(6):265—2T1 (2000)
`
`.CHMITZ, K. et al., "Interaction of antibodies with ErbB receptor extracellular regions," Exp Cell Res., vol. 315(4):
`. 59—670 (2009)
`
`(.71O
`
`.OLTOFF, SP. et al., "Erst Is Involved in Activation of Phosphatidylinositol 3—Kinase by Epidermal Growth Factor,"
`ol Cell Biol., vol. 14(6): 3550-3558 (1994)
`
`EFS Web 2.1.17
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Application Number
`15121623
`
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`| 1642
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`I MRX5-01TUS
`
`
`
` If you wish to add additional non-patent literature document citation information please click the Add button
`
`EXAMINER SIGNATURE
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if
`English language translation is attached.
`
`EFS Web 2.1.17
`
`

`

`
`
`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Application Number 15121623
`
`Filing Date
`2016-08-25
`First Named Inventor
`Cecilia Anna Wilhelmina GEUIJEN
`
`Art Unit
`|1542
`
`
`
` Attorney Docket Number
`
`
`
`Examiner Name
`Not Yet Assigned
`I MRX5-017US
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`OR
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`El
`
`See attached certification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`X A certification statement is not submitted herewith.
`
`SIGNATURE
`
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form andlor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFS Web 2.1.17
`
`
` NamelPrint
`Signature
`2017—03—10
`
`
`
`
`
`